Amgen's Prolia beats Zometa in final Phase III bone metastases trial
09 February 2010
Asher Mullard
Amgen's Prolia (denosumab) was superior to Novartis's bisphosphonate Zometa (zoledronic acid) in delaying bone complications in prostate cancer patients with bone metastases, show top-line Phase III data.
Before the data was announced, Jefferies analysts commented that positive data from this...
Please Login to read the full article.
09 February 2010
Asher Mullard
Before the data was announced, Jefferies analysts commented that positive data from this...
Please Login to read the full article.
RELATED CONTENT
NEWS
- A year in pharma and biotech R&D: Healthy numbers belie lack of novelty
- Amgen reports 'striking' results for Xgeva in delaying prostate cancer bone metastases
- Japanese denosumab approval furthers Daiichi Sankyo's oncology ambitions
- Amgen files Xgeva in US for prostate cancer prevention
ANALYSIS
Other Informa Analysis
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
